FAS and rheumatoid arthritis: Moreover, a new type of recombinant fusion protein scFvCD7, developed on the pretext that CD7 targets sFasL that specifically binds to T cells, can selectively activate the Fas/FasL signaling pathways in Th1 and Treg cells to induce autoimmune T cell apoptosis and thus, possesses a promising therapeutic value for RA (70).